Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 12, 1179550619828683
eCollection

Depression, Hematologic Parameters, and Blood Levels of Vitamin B 12 in Patients With Laryngopharyngeal Reflux Under Use of Proton Pump Inhibitors

Affiliations

Depression, Hematologic Parameters, and Blood Levels of Vitamin B 12 in Patients With Laryngopharyngeal Reflux Under Use of Proton Pump Inhibitors

Rebecca Heidrich Thoen Ribeiro et al. Clin Med Insights Ear Nose Throat.

Abstract

Objective: The objective of this study was to evaluate and correlate hematologic indices, vitamin B12 levels, and depression in patients with suspected laryngopharyngeal reflux (LPR) treated with proton pump inhibitor (PPI).

Methods: This was a prospective study with a population (n = 23) consisted of patients with suspected LPR and treated with 2 daily doses of Omeprazole 40 mg (80 mg or full dose). The study volunteers performed a complete blood count and vitamin B12 dosage before and after 3 and 6 months of treatment, as well as depression screening using the Center of Epidemiologic Studies-Depression (CES-D) questionnaire before and after 6 months of treatment. Scores greater than 16 were considered as suggestive of depression.

Results: The mean score on the CES-D scale of study participants at baseline significantly decreased after 6 months of treatment. A significant decrease was observed in the red blood cells count (RBC) after 6 months in relation to 3 months. Significant increases in mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH) were observed from 3 months to 6 months in this study. Vitamin B12 levels increased significantly between baseline and after 6 months of treatment.

Conclusion: Decreased scores on the CES-D scale were associated with increased MCV values, with no association with vitamin B12 levels. However, vitamin B12 levels also increased significantly after 6 months of treatment with PPI.

Keywords: B12 vitamin; Laryngopharyngeal reflux; blood count; depression; proton pump inhibitor.

Conflict of interest statement

Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Inclusion criteria used in the study.

Similar articles

See all similar articles

References

    1. Ford CN. Evaluation and management of laryngopharyngeal reflux. JAMA. 2005;294:1534–1540. - PubMed
    1. Abou-Ismail A, Vaezi MF. Evaluation of patients with suspected laryngopharyngeal reflux: a practical approach. Curr Gastroenterol Rep. 2011;13:213–218. - PubMed
    1. Vaezi MF. Laryngitis: from the gastroenterologist’s point of view. In: Vaezi MF, editor. ed. Extraesophageal Reflux. San Diego, CA: Plural; 2009:37–47.
    1. Sataloff RT, Hawkshaw MJ, Gupta R. Laryngopharyngeal reflux and voice disorders: an overview on disease mechanisms, treatments, and research advances. Discov Med. 2010;10:213–224. - PubMed
    1. IMS Health. A review of the use of medicines in the United States in 2012. www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IM2013.

LinkOut - more resources

Feedback